Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Arribas, José R.; Eron, Joseph J.; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Petrovic, Romana; Vanveggel, Simon; Opsomer, Magda; Ajana, F.; Arribas, Jr; Bailey, J.; Benson, P.; Gathe, Joseph; Berenguer, J.; Bhatti, L.; Blaxhult, A.; Brar, I.; Bredeek, Uf F.; Brinson, C.; Molina, Jean-Michel; Brunetta, J.; Casado, J.; Clarke, A.; Orkin, Chloe; Conway, B.; Negredo, Eugenia; Cotte, L.; Crofoot, G.; Cunningham, D.; de Vente, J.; De Wit, S.; DeJesus, E.; Gathe, J.; Dietz, C.; Dretler, R.; Eron, J.; Fehr, J.; Felizarta, F.; Fichtenbaum, C.; Flamholc, L.; Florence, E.; Galindo, Mj J.; Gallant, J.; Gasiorowski, J.; Gatell, Jm M.; Gazzard, Bg G.; Molina, J.-M.; Girard, P.-M.; Gisslèn, M.; Gutierrez, F.; Gutierrez, Mdm D. M.; Hagins, D.; Halota, W.; Negredo, E.; Henn, S.; Orkin, C.; Henry, Wk K.; Horban, A.; Huhn, G.; Iribarren, Ja A.; Jain, M.; Johnson, Ma; Katlama, C.; Klein, M.; Knobel, H.; Lucasti, C.; Martorell, C.; McDonald, C.; Mills, A.; Morales-Ramirez, J.; Mounzer, K.; Moutschen, M.; Murphy, D.; Nahass, R.; Olivet, H.; Osiyemi, O.; Perez-Valero, I.; Piekarska, A.; Pineda, Ja A.; Podzamczer, D.; Poizot-Martin, I.; Portilla Sogorb, J.; Post, F.; Prelutsky, D.; Pulido, F.; Rachlis, A.; Raffi, F.; Ramgopal, M.; Rashbaum, B.; Rauch, A.; Rey, D.; Reynes, J.; Ricart, C.; Richmond, G.; Rivero, A.; Ruane, P.; Gil, I. Santos; Scarsella, A.; Scribner, A.; Shafran, S.; Shalit, P.; Shamblaw, D.; Slim, J.; Stoeckle, M.; Tashima, K.; Teicher, E.; Thalme, A.; Ustianowski, A.; Van Wijngaerden, E.; Vandekerckhove, L.; Vandercam, B.; Voskuhl, G.; Walmsley, S.; Ward, D.; Waters, L.; Wilkin, A.; Witor, A.; Yazdanpanah, Y.

Published in

The Lancet HIV, 1(5), p. e23-e34

DOI: 10.1016/s2352-3018(17)30179-0

Tools

Export citation

Search in Google Scholar

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Journal article published in 2018 by José R. Arribas, Joseph J. Eron, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Romana Petrovic, Simon Vanveggel, Magda Opsomer, F. Ajana, Jr Arribas, J. Bailey, P. Benson, Joseph Gathe, J. Berenguer, L. Bhatti and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving forbidden

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools